

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Dan P. Felsenfeld et al.

Application No.: 10/561,015

Confirmation No.: 9430

Filed: February 17, 2006

Art Unit: 1649

For: METHODS AND AGENTS FOR TREATING
AXONAL DAMAGE, INHIBITION OF
NEUROTRANSMITTER RELEASE AND
PAIN TRANSMISSION, AND BLOCKING
CALCIUM INFLUX IN NEURONS

Examiner: Steven H. Standley

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement mailed April 3, 2008, a Petition for an Extension Of Time for one month up to and including June 3, 2008 and the requirements being filed concurrently herewith, Applicants hereby elect the invention of Group 2, claims 5-7 for prosecution, with traverse.

Applicants respectfully submit that the claims in this application relate to a single general inventive concept under PCT Rule 13.1 because they are linked by a corresponding special technical feature, i.e., the polypeptide of SEQ ID NO.: 2 (of Group 2) and its use in a method for promoting outgrowth of mammalian neurons by administering said polypeptide (Group 1).

In addition, the special technical feature of Group 2 is not known in the prior art. The peptide of claim 5 (SEQ ID NO.: 2) is derived from the cytoplasmic domain of the L1-CAM